Related Experiment Video

Updated: May 22, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Targeting NF-κB in mouse models of lung adenocarcinoma

Carter Van Waes1

  • 1Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland 20892, USA. vanwaesc@nidcd.nih.gov

Cancer Discovery
|May 16, 2012
PubMed

Insights

Xue et al. found that while Kras-activated, p53-deficient adenocarcinomas initially respond to NF-κB pathway inhibitors, acquired resistance eventually develops. This highlights challenges in targeting this pathway for cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • The NF-κB signaling pathway is frequently dysregulated in various cancers, including Kras-driven adenocarcinomas.
  • Targeting the NF-κB pathway with proteasome or IKK inhibitors has shown promise in preclinical cancer models.

Purpose of the Study:

  • To investigate the efficacy and resistance mechanisms of NF-κB pathway inhibitors in Kras-activated, p53-deficient adenocarcinomas.
  • To evaluate the impact of these inhibitors on tumor response and survival in a relevant preclinical model.

Main Methods:

  • Utilized a Kras-activated, p53-deficient mouse model of adenocarcinoma.
  • Administered proteasome inhibitors and inhibitor-κB kinase (IKK) inhibitors targeting the NF-κB pathway.
  • Assessed tumor response, survival rates, and characterized resistance mechanisms.

Main Results:

  • Demonstrated initial tumor response and increased survival in mice treated with NF-κB inhibitors.
  • Observed the development of acquired resistance to both proteasome and IKK inhibitors over time.
  • Identified specific mechanisms contributing to the emergence of resistance.

Conclusions:

  • NF-κB pathway inhibition can induce a response in Kras-driven adenocarcinomas but is ultimately limited by acquired resistance.
  • Understanding resistance mechanisms is crucial for developing durable therapeutic strategies targeting the NF-κB pathway in cancer.
  • Further research is needed to overcome resistance and improve patient outcomes in these specific cancer types.

More Related Videos

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...